09:35:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-21 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2021-01-20 08:00:00
OSLO/LONDON, JANUARY 20 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company today announced a
collaboration with GE Healthcare to develop an innovative ultrasound probe to be
used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across
multiple disease conditions.

"We are delighted to collaborate with GE Healthcare, a leader in the field of
diagnostic imaging and ultrasound. We look forward to working closely with GE
Healthcare in developing an innovative ultrasound probe with the goal of
enabling effective deployment of the ACT® therapeutic amplification platform
across indications for our forthcoming phase II clinical development program",
said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.

ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. ACT® is
supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as controlled blood-brain barrier opening. Currently ACT® is being
evaluated in the international ACTIVATE Phase I clinical trial in patients with
metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in
London.


About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com


For more information contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu